Research Strategy and Studies

A summary of our 2018-2021 research strategy can be viewed here.

The list below shows current studies in the Academic Directorate of Respiratory Medicine. For further information please contact 


  • CF – Cystic Fibrosis
  • COPD – Chronic Obstructive Pulmonary Disease
  • ILD – Interstitial Lung Disease
  • Inf / Imm - Inflammation & Immunity
  • PH – Pulmonary Hypertension
  • MRC - Medical Research Council
  • NIHR – National Institute for Health Research

For further information please contact

Theme Principal Investigator Title Funder
Asthma Sabroe Screening of target genes for polymorphic variation which may alter treatment response for airway management Asthma UK
Asthma Sabroe Study of mechanisms of action of Omalizumab in severe asthma Novartis Pharmaceuticals UK Ltd
Asthma Sabroe An observational study of the use of lung MRI imaging for patient benefit MRC
Asthma Sabroe Co-morbidity and refractory asthma - data from a UK registry BTS Asthma Registry
CF Edenborough Cystic Fibrosis Registry Cystic Fibrosis Trust
CF Wildman ACtiF - Adherence to treatment in adults with Cystic Fibrosis 2.1C NIHR Programme Grants
CF Wildman CF Health Hub Data Observatory NHS England
CF Wildman Hyperpolarised gas MRI and multiple breath inert gas washout to improve management and understanding of cystic fibrosis lung disease. NIHR
CF Wildman A pilot study to investigate the role of self-monitoring symptoms using daily diaries, to increase adherence to nebuliser treatments in adults with Cystic Fibrosis Sheffield Hallam University
COPD Lawson Lung magnetic resonance Imaging with FluorocarbonTracer gases Medical Research Council
COPD Lawson A Phase IIb, Placebo-Controlled, Dose-Finding Study of Nemiralisib (GSK2269557) Added to Standard of Care (SoC) Versus SoC Alone in Participants Diagnosed with an Acute Moderate or Severe Exacerbation of COPD GlaxoSmithKline
ILD Bianchi The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary Fibrosis with the addition of Co-trimoxazole (EME-TIPAC) NIHR Efficacy and Mechanism Evaluation Programme
ILD Bianchi Investigation into prognostic indicators of Idiopathic Pulmonary Fibrosis using structural-functional pulmonary MRI assessment NIHR
ILD Bianchi Functional MRI and PETCT in Idiopathic Pulmonary Fibrosis NIHR
ILD Bianchi A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib co-administered with oral sildenafil, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment Boehringer Ingelheim Ltd
ILD Bianchi Development of imaging biomarkers for the detection and monitoring of drug induced interstitial lung disease (TRISTAN) European Innovative Medicines Initiative
ILD Bianchi Multi-center, international, double-blind, two-arm, randomized, placebo-controlled phase II trial of pirfenidone in patients with unclassifiable progressive fibrosing ILD Hoffman-La Roche
ILD Renshaw Identification of disease susceptibility genes and autoantibodies associated with the development and clinical characteristics of interstitial lung disease (ILD) in patients with and without proven connective tissue diseases (CTDs). University of Liverpool
Inf/Imm Sabroe The control of innate immunity, host pathogen interactions, and leukocyte function in healthy volunteers Medical Research Council
Mesothelioma Lewis Randomised controlled trial to compare the diagnostic yield of Positron Emission Tomography Computed Tomography TARGETed pleural biopsy versus CT guided pleural biopsy in suspected pleural malignancy North Bristol NHS Trust
PH Armstrong Evaluation of patient experiences of Inhaled Iloprost using the Breelib nebulizer Pulmonary Hypertension Association
PH Charalampopoulos SERENADE: A multi-center, double-blind, placebo-controlled Phase 2b study to evaluate the efficacy and safety of macitentan in subjects with heart failure with preserved ejection fraction and pulmonary vascular disease Actelion Pharmaceuticals
PH Condliffe Long term, multicenter, single-arm, open-label extension study of the MERIT-1 study, to assess the safety, tolerability and efficacy of macitentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) merit Actelion Pharmaceuticals
PH Condliffe A prospective, randomized, international, multicenter, double-arm, controlled, open-label study of Riociguat in patients with pulmonary arterial hypertension (PAH) who are on a stable dose of phosphodiesterase-5 inhibitors (PDE-5i) with or without endothelin receptor antagonist (ERA), but not at treatment goal (REPLACE) Bayer Plc
PH Kiely Assessing the Spectrum of Pulmonary Hypertension In a Referral Centre (ASPIRE) STH NHS FT
PH Kiely Freedom 304: TDE-PH-304: “An Open-Label Extension Trial of  UT-15C SR in Subjects with Pulmonary Arterial Hypertension United Therapeutics Corporation
PH Kiely Pilot study: Use of Functional MRI to understand the pathophysiology of abnormalities of gas exchange in patients with idiopathic pulmonary fibrosis and systemic sclerosis UoS Department
PH Kiely Sheffield Pulmonary Hypertension Biobank British Heart Foundation
PH Kiely National Cohort Study of Idiopathic and Heritable Pulmonary Arterial Hypertension BHF/MRC
PH Kiely Isolation and characterisation of blood-derived progenitor cells in patients with cardiovascular disease and TGF-beta superfamily related diseases MRC
PH Kiely A prospective, multicenter, single-arm, open-label, Phase 4 study to evaluate the effects of macitentan on Right vEntricular remodeling in Pulmonary ArterIal hypeRtension assessed by cardiac magnetic resonance imaging - REPAIR Actelion Pharmaceuticals
PH Kiely Investigation into predictors of diagnosis in PAH patients IQVIA / GSK
PH Kiely A multi-center, double-blind, placebo-controlled, Phase 4 study in patients with pulmonary arterial hypertension to assess the effect of selexipag on daily life physical activity and patient’s self-reported symptoms and their impacts (TRACE trial) Actelion Pharmaceuticals
PH Rothman Clinical evaluation of the Therapeutic Intra-Vascular Ultrasound (TIVUS) system for pulmonary artery denervation in patients with pulmonary hypertension. (TROPHY) Sonivie
PH Swift Reproducibility of Magnetic resonance imaging cardiopulmonary metrics in healthy volunteers and patients with pulmonary arterial hypertension – Implications for trial design GSK

Related Staff

Dr Jim Lithgow
Research Coordinator
Dr Lisa Watson
BSc, PhD
Research Coordinator
Prof Ian Sabroe
Consultant and Professor of Inflammation Biology; Co-Director, Medical Humanities Sheffield